Corp. Gc Acquires 1,085,069 Shares of Artiva Biotherapeutics (NASDAQ:ARTV) Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) major shareholder Corp. Gc acquired 1,085,069 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The shares were acquired at an average cost of $11.52 per share, with a total value of $12,499,994.88. Following the purchase, the insider owned 4,391,969 shares in the company, valued at $50,595,482.88. This represents a 32.81% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Corp. Gc also recently made the following trade(s):

• On Monday, May 11th, Corp. Gc acquired 347,222 shares of Artiva Biotherapeutics stock. The shares were acquired at an average cost of $11.52 per share, with a total value of $3,999,997.44.

Artiva Biotherapeutics Price Performance

NASDAQ ARTV traded down $0.02 during trading hours on Thursday, hitting $7.61. 216,414 shares of the company’s stock traded hands, compared to its average volume of 313,092. Artiva Biotherapeutics, Inc. has a 52-week low of $1.47 and a 52-week high of $14.53. The company has a market capitalization of $188.12 million, a PE ratio of -2.15 and a beta of 2.86. The firm’s 50-day moving average is $8.50 and its 200-day moving average is $5.82.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.07). Equities research analysts predict that Artiva Biotherapeutics, Inc. will post -2.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Friday, April 24th. Cantor Fitzgerald reissued an “overweight” rating on shares of Artiva Biotherapeutics in a research note on Tuesday. HC Wainwright increased their price target on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Wedbush increased their price target on shares of Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an “outperform” rating in a research note on Monday, May 11th. Finally, Wall Street Zen cut shares of Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, May 17th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $39.00.

Hedge Funds Weigh In On Artiva Biotherapeutics

Hedge funds have recently made changes to their positions in the stock. Marshall Wace LLP purchased a new position in shares of Artiva Biotherapeutics during the 4th quarter worth approximately $341,000. Jane Street Group LLC purchased a new position in shares of Artiva Biotherapeutics during the 4th quarter worth approximately $174,000. Landscape Capital Management L.L.C. purchased a new position in shares of Artiva Biotherapeutics during the 3rd quarter worth approximately $112,000. BNP Paribas Financial Markets boosted its position in shares of Artiva Biotherapeutics by 14,463.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock worth $340,000 after purchasing an additional 117,733 shares during the period. Finally, Qube Research & Technologies Ltd purchased a new position in shares of Artiva Biotherapeutics during the 2nd quarter worth approximately $58,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.